Response to the letter to the editor entitled "Forty-two-month outcome of intravitreal bevacizumab in myopic choroidal neovascularization"

Graefes Arch Clin Exp Ophthalmol. 2016 Apr;254(4):811. doi: 10.1007/s00417-015-3171-3. Epub 2015 Sep 10.

Authors

Gian Marco Tosi¹, Claudio Traversi², Elisabetta Nuti², Davide Marigliani²

Affiliations

¹ Ophthalmology Unit of the Department of Medicine, Surgery and Neuroscience, University of Siena, Viale Bracci 1, 53100, Siena, Italy. gmtosi@tin.it.
² Ophthalmology Unit of the Department of Medicine, Surgery and Neuroscience, University of Siena, Viale Bracci 1, 53100, Siena, Italy.

PMID: 26358272
DOI: 10.1007/s00417-015-3171-3

No abstract available

Publication types

Letter
Comment

MeSH terms

Angiogenesis Inhibitors / therapeutic use
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Bevacizumab*
Choroidal Neovascularization / drug therapy*
Humans
Intravitreal Injections
Myopia, Degenerative / drug therapy
Tomography, Optical Coherence
Treatment Outcome
Vascular Endothelial Growth Factor A
Visual Acuity

Substances

Angiogenesis Inhibitors
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Vascular Endothelial Growth Factor A
Bevacizumab